Evaxion Biotech A/S's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 206 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.25.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evaxion Biotech A/S's Score
Industry at a Glance
Industry Ranking
206 / 387
Overall Ranking
378 / 4564
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evaxion Biotech A/S Highlights
StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 10212.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.53M.
Undervalued
The company’s latest PE is -15.38, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 323.61K shares, increasing 1.65% quarter-over-quarter.
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.